



Technical Market View

It was a quieter week for **S&P Futures (ES_F)** which finished lower for the week, albeit largely rangebound between 4280 and 4385. Short-term momentum remains cautious with the declining 21-EMA a headwind all week but the 8-day is starting to flatten out and we continue to form a series of higher lows on the shorter-term timeframe. Momentum is mixed with MACD recently crossing over bullish but unable to follow-through while RSI is back near the 50-level but starting to roll over. We continue to trade in a channel lower from the January highs but back above the mid-point of the range and room up to 4415 and then breakout of the pattern with upside targets of 4525-4550. There's also a notable high-volume node at 4570. A move lower has support at 4235 and then 4150. The channel low would target 4050.



Market Sentiment/Breadth

AAll sentiment for the week ending 3/2 showed bulls rise to 30.4% from 23.4% prior and bears fall to 41.4% from 53.7%. Neutral sentiment rose to 28.2% from 22.9%. Optimism overall is nearing its highest levels of the year but remains well below average. NAAIM Exposure fell to 30.3 vs 44.41 prior and now the lowest since April 2020 when it hit 28.71. Lipper Fund flows had \$1.8B of inflows to equities, the fourth straight week of positive flows. As of Friday's close there were 278 new highs versus 911 new lows, weaker breadth. The percentage of stocks above their 50-MA was 27.9% while those above their 200-MA was 26.9%, both remain well below bullish levels. NYSE Summation was -679 and sitting right at the 8-EMA, so potential to watch for a push and sustained move above this week. NASI closed right on its 8-EMA also, so another inflection point for sentiment. Cumulative AD remains in a bear trend and the 8-/21-week EMA also in a bear trend. CBOE Equity P/C 50-day MA closed at 0.59 and remains neutral overall. CNN Fear and Greed closed at 17 and down from 33 last week.

Seasonality Outlook

Per the Trader's Almanac,

- March is the 3rd best Nasdaq month during midterm election years, avg gain +1.3%.
- The Utilities sector starts seasonal bullish bias in mid-March going into October. Average returns for this time period the last 10 years are +8.2%, for last 5 years is +11.6%
- March is historically stronger early in the month and weaker after OPEX.
- Monday before March Quad Witching, Dow is up 24 of last 34 years.

Below shows the daily odds the market has been up each day since the year 2000. The second week of March shown below has generally had an upside bias especially towards the end of the week with the S&P the stronger index overall. This week has tended to be weak to start with more strength by Wednesday which generally pushed into March quad witching OPEX week. The Dow in particular has shown the strongest bull bias during March OPEX week. The Thursday of OPEX week has historically been the strongest day overall.

	Seasonality Percentages					since year 2000
	Monday	Tuesday	Wednesday	Thursday	Friday	Weekly Avg
	3/7/2022	3/8/2022	3/9/2022	3/10/2022	3/11/2022	
Dow	47.6	47.6	61.9	47.6	57.1	52.4
S&P	47.6	47.6	61.9	52.4	61.9	54.3
Nasdaq	33.3	47.6	52.4	47.6	61.9	48.6
Average	42.8	47.6	58.7	49.2	60.3	51.7
	Monday	Tuesday	Wednesday	Thursday	Friday	Weekly Avg
	3/14/2022	3/15/2022	3/16/2022	3/17/2022	3/18/2022	
Dow	61.9	71.4	57.1	61.9	57.1	61.9
S&P	38.1	57.1	61.9	66.7	42.9	53.3
Nasdaq	42.9	42.9	66.7	71.4	66.7	58.1
Average	47.6	57.1	61.9	66.7	55.6	57.8

Market Event Outlook

Monday: Consumer Credit; **International Data:** China Import/Exports, German Factory Orders; **International Earnings:** Playtech; **Earnings Before the Open:** CIEN, SQSP; **Earnings After the Close:** MASS, AVDX, ROVR, TDUP; **Analyst Days:** KSS, LAZR; **Conferences:** Morgan Stanley TMT (NATI, NTAP, ANET, SWI, SQSP, KN, OPEN, TV, AVL, OTEX, AKAM, DOX, DOCS, IOT, INST, JMIA, NET, QLYS, LGF.B, USER, SEMR, CMCSA, V, MSFT, WDC, CWAN, AXON, GLW, MTTR, GOOG, GOOGL, GPRO, DBX, WKME, TXN, DAVA, NOK, NXPI, BCE, COMM, SNOW, NVDA, STX, SFIX, PEGA, APPN, AFRM, DIOD, TSP, NOW, AI, IS, VMW, EXTR, TEAM, CRTO, CFLT, UPST, KLAC, CRUS, HLTH, NTN, VRNA, BMBL, PYPL, RAMP, EQIX, SNPO, ZEN, CCO, VIAV, REZI, SPOT, TOST, PANW, BAND, LUMN, KEYS, ONTO, FRSH, ZI), JMP Tech (ALKT, PLAN, ANET, ARLO, AVL, BLZE, BL, CMBM, NET, CCSI, CYBR, DDOG, DOCN, DV, LZ, LVOX, MODN, NICE, NEWR, OOMA, PCTY, PEGA, PHR, XM, QLYS, SSTK, SWI, SPSC, TBLA, TDC, TNET, TRUE, TWLO, VRNS, VEEV, WKME, ZEN, ZD, VERI, GLBE, UPWK, EVER, ZS, DBX, SNOW, DT, NOW, AI, ACVA, UPST, SMWB, TYL, OB, FRSH, HOOD, BKKT, BILL, AUGX, ENV, EVCM, ZM, ROVR,

PYCR, ADTH, PUBM, APRN, PL, DOMA, DSP, SSTI, NRDY, DOMO, SOFI), Cowen Healthcare (EBS, NVS, SGFY, STRO, ALLO, TNYA, SWTX, PRCT, RLAY, CTSO, NVTA, GILD, GLUE, ROIV, MYOV, GH, JNJ, MASS, PACB, CANO, ATEC, VYGR, NKTX, BMRN, ISO, BPMC, TNDM, RNA, TSVT, CI, MXCT, HCA, IVA, TKNO, ADAP, INCY, NTRA, SYK, PODD, NAUT, CTKB, SCPH, EW, ABSI, PNT, REGN, RPRX, CCCC, TDOC, QSI, MCK, CFMS, ILMN, RNLX, LLY, ELAN, AKYA, AVTE, HZNP, TBPH, NUVA, OLMA, ALHC, QTNT, BIIB, OM, GDRX, SEER, TYRA, TMDX, ITOS, PTCT, VERV, XOMA, SNCE, TRDA, IMGN, RPID, UHS, GRTS, RCEL)

Tuesday: NFIB Small Business Optimism, Imports/Exports, Redbook, API Inventories; **International Data:** Japan Employment, German Industrial Production, Taiwan Import/Exports; **International Earnings:** Ashtead Group, Andritz; **Earnings Before the Open:** DM, DKS, OLPX, WOOF, STVN; **Earnings After the Close:** ABM, BMBL, CASY, CRCT, DV, FIGS, GWRE, MDB, SFI, SUMO, WTI, YEXT; **Analyst Days:** LITE, PH, POOL, GTES, FISV; **Conferences:** Morgan Stanley TMT, JMP Tech, Cowen Healthcare, Wolfe Fintech (V, DFS, DBD, GS, WU, PYPL, FOUR, AVDX, TOST, ML, PAYO, BKKT, ENV, COIN, MA, FLT, BILL, ADS, GPN, WEX, AMK, FIS, FLYW, JKHY, PSFE, RPAY, LPLA), BAML Retail (FRPT, RVLV, XPOF, CENT, CENTA, BIRD, SNA, TPR, HLF, BBY, QRTEA, DRVN, CLAR, DKS, ACCO, LVLU, RCII, WMT, FNKO, TPX, BIG, OSTK, OLPX, BKNG)

Wednesday: Mortgage Applications, JOLTs, EIA Inventories, WASDE; **International Data:** China CPI/PPI; **International Earnings:** Deutsche Post, Adidas, Vivendi, Siltronic; **Earnings Before the Open:** CPB, DSEY, EBIX, KFY, OTLY, REVG, PLCE, THO, UNFI, VRA, VERX; **Earnings After the Close:** ASAN, CVGW, BASE, CRWD, FNV, BEKE, MQ; **Analyst Days:** DIN, WWD, HRB, WAB, SONO; **Conferences:** Morgan Stanley TMT, Cowen Healthcare, Wolfe Fintech, BAML Retail, UBS Consumer/Retail (VSTO, M, TSCO, TCS, SY, SMG, CL, MCD, SFM, LOW, SHAK, SKX, WMT, EXPR, POOL, EYE, QSR)

Thursday: CPI, Weekly Claims; **International Data:** Japan PPI, ECB Meeting; **International Earnings:** K+S, Hugo Boss; **Earnings Before the Open:** BZUN, CLVT, DCBO, AG, GCO, JD, LTH, PTLO, THRY, UP; **Earnings After the Close:** AOUT, BLNK, CMTL, DOCU, LOCO, LZ, LFST, MLNK, AVO, FIZZ, ORCL, RRGB, RIVN, SHLS, ULTA, WPM, ZUMZ; **Analyst Days:** EBAY, GE, MNDT, WMS, DB, MCO; **Conferences:** Morgan Stanley TMT, Wolfe Fintech, UBS Consumer/Retail

Friday: Michigan Consumer Sentiment; **International Data:** UK GDP, UK Industrial Production; **International Earnings:** EssilorLuxottica, Lanxess; **Earnings Before the Open:** GENI, PLXP; **Analyst Days:** AT&T (T), AGL, SPNE

Weekly Open Interest Radar

Boyd Gaming (BYD) shares dipping on Friday back to the rising 55-EMA but remaining in a bullish trend overall with shares flagging just above a big range that stretches back to early 2021. The broader range breakout and continuation of the long-term trend targets a run up to \$82+. BYD has seen notable bull spreads lately including the June \$80/\$60 bull risk reversal opened 2000X1000 on 2/10, the July \$55 calls bought on 1/19, and the June \$75/\$100 call spread bought on 11/24 with the \$45 puts sold to open.

Trade to Consider: Long the **BYD** June \$70 Calls for \$5.40 or Better

Date	Description	Volume	Open Int	Price	Delta	Impl Vo	Prob. ITM	Premium Paid
2/10/2022	BYD 100 17 JUN 22 80 CALL	2,160	25	\$3.60	0.36	39.38%	27.96%	\$864,000
2/10/2022	BYD 100 17 JUN 22 60 PUT	1,000	19	\$2.30	-0.21	44.27%	28.97%	\$275,000
1/19/2022	BYD 100 15 JUL 22 55 CALL	384	0	\$8.73	0.63	42.81%	51.17%	\$335,232
11/24/2021	BYD 100 17 JUN 22 100 CALL	1,500	4	\$0.45	0.08	41.24%	4.39%	\$112,500
11/24/2021	BYD 100 17 JUN 22 45 PUT	1,500	2	\$1.60	-0.13	45.47%	22.20%	\$270,000
11/24/2021	BYD 100 17 JUN 22 75 CALL	1,500	5	\$3.50	0.32	40.91%	21.77%	\$525,000
10/13/2021	BYD 100 19 JAN 24 30 PUT	1,750	0	\$2.25	-0.06	43.70%	18.35%	\$393,750
7/20/2021	BYD 100 20 JAN 23 55 CALL	351	30	\$10.89	0.6	44.32%	38.27%	\$382,239

Weekly Options Technical Trade Set-Up

Ticker	HAL
Trigger Level	\$34.30
Call/Put	Calls
Strike	\$34.50
Target	\$36
Stop	\$32.85



Credit Spread of the Week

Top EV Leader Ready to Rebound from Bull Wedge

Tesla (TSLA) - TSLA is a \$947B leader in electric vehicles and one of the few growth stocks which can say they are still up positive year over year as the stock was much closer to 600 this time last year before its wild run up to 1240 in the Fall. TSLA still has an impressive 3 year compounded annual growth rate of 48% and has been thrown out with the interest rate fears. The stock has corrected back to its yearly VPOC support at near 700 and recovered sharply off that level to end February back near 870. The past week spent flagging right near its 200-day EMA and trying to turn the corner higher out of a falling bullish wedge pattern from the highs. TSLA has the potential to curl up and breakout past its YTD VPOC near 910 with a decent volume pocket above that towards 1025. The recent lows made last month also were met with positive bull RSI divergence showing even more evidence the momentum is running out on the downside and should turn higher. Additionally, the seasonality in April for TSLA is impressive. Being up an average of 10% in April the past 10 years. The stock often does its own thing compared to the Nasdaq but even if the overall market stabilizes after mid-March, there's a good probability that TSLA leads the upside into a market wide rebound as sentiment is overwhelmingly bearish and primed for a rally. Options flows in TSLA see a lot of activity on both sides but some of the more recent larger long-term bets are decidedly bullish. On 2/25 Tesla buyers of 1000 December \$950 calls for \$10.4M, also 2000 Dec. \$1000 calls for \$18M, and 1400 of the Dec. \$1050 calls for \$12M. TSLA also a buyer of 1000 July \$1050 calls for \$34. On 2/16 a large opening put sale for 3100 of the April \$900 puts at \$67.50 for over \$21.4M in premium collected and still in OI showing confidence in a rally back to 900 by April expiration.

Trade to consider: Sell **TSLA** April 800/780 bull put spread for \$7.50 credit or better.



Insider Trade of the Week

Crocs (CROX) with two notable insider buys in the last two weeks from directors Thomas Smach and Douglass Treff, each buying on 2/17 and 3/3. Smach bought \$1.5M in stock between \$78 and \$86 while Treff bought \$1.5M in stock at \$78 to \$91.50. These are the first open market buys in the name since March 2020 and largest since 2008. CROX has been in an ugly trend since December 2021 and now over 60% off its 52-week high. Shares are just below the 61.8% Fibonacci retracement of the massive rally since March 2020 and into a low-volume node from \$72-\$67. A near-term bounce has room to \$84 and then \$101.50, a major HVN. The \$4.2B company trades 5.8X earnings, 1.82X sales, and 8.2X FCF. CROX is coming off a record year with 67% revenue growth, an industry-best 30% operating margins and adding new products to the lineup including a major deal for HEYDUDE which should help drive them towards their \$6B five-year revenue target. The company faces tough comps going forward and a deceleration in near-term growth but they're positioned well for the longer-term with a big emphasis on digital sales, targeting 4X growth in the \$30B sandals market, and expanding in Asia which they note is the second largest footwear market in the world. Analysts have an average target for shares of \$167 with a Street High \$246. Baird remains positive on the name noting the upside case looks compelling for patient investors as meetings with management increased confidence in the current outlook for both Crocs and HEYDUDE. Stifel positive on 1/18 but lowering their estimates. The firm thinks the acquisition of the high-growth, high-margin HeyDude business eases the dependence on clogs and thinks the operating margin targets for both Crocs and HeyDude appear to present a low-hurdle. Hedge fund ownership rose 2.5%. Samlyn Capital a buyer of call options while Victory Capital adding stock. Short interest is 6.3%. Options flow has been bearish with 1750 June \$100 calls sold to open while the April \$80/\$70 put spread opened 5000X on 2/17.

Earnings Preview

Ulta Beauty (ULTA) reporting earnings on 3/10 after the close with the Street looking for \$4.55 on \$2.69B in sales. Next quarter is guided to \$4.28 on \$2.06B while the FY is \$17.16 on \$8.59B. Shares have closed lower in four of the last five with an average closing move of 3.9% and a max move of 8.45%. The current implied move is 7.87%. The \$19.6B company trades 20.5X earnings, 2.4X sales, and 23.8X FCF. ULTA is coming off of a strong quarter with 25.8% comps, expanded market share, and significant growth in their loyalty program. The company recently held an analyst day outlining their goals for the medium-term noting that the US beauty and personal care market is returning to growth after deceleration in 2019/2020 while their leadership in key categories like makeup and skincare give them strong positioning. ULTA could see a boost to sales this quarter due to the full launch of prestige brand Olaplex, growth in mass

makeup due to an increased return to socialization and new products, and the expansion of their Target in-store footprint to 100 stores. Analysts have an average target for shares of \$449 with a Street High \$516. Raymond James with a \$450 PT for shares. They expect Ulta to have a strong quarter and is estimating 20% y/y comp sales growth driven by 13% growth in transactions and 7% growth in ticket. JP Morgan positive on 1/14 noting that Ulta remains in an early re-open phase given the rebound in prestige cosmetics. Evercore has a \$500 PT and noting that while the company continues to be a key beneficiary of the reopening, they also have many innovative products and initiatives in the pipeline to drive growth into 2022/2023. Hedge fund ownership fell 5.5%. Short interest is 3.1%. Options flow has been bullish with buyers recently in the March \$347.50 calls for \$1.145M and the June \$365 calls remain in OI from 2/4 buys over \$670K. The March \$365 and \$380 calls also had buyers in January. ULTA is forming a multi-week consolidation above VWAP from the November 2020 gap higher that kick-started the recent rally. Support is near \$337 and underneath has room to move to \$315. A breakout move targets the prior highs near \$400.

Date	Description	Volume	Open.Int	Price	Delta	Impl Vo	Prob.ITM	Premium Paid
3/4/2022	ULTA 100 18 MAR 22 347.5 CALL	378	0	\$30.30	0.677	71.14%	62.63%	\$1,145,340
2/28/2022	ULTA 100 16 SEP 22 415 CALL	200	0	\$28.20	0.42	41.10%	30.49%	\$564,000
2/4/2022	ULTA 100 17 JUN 22 365 CALL	179	22	\$37.44	0.554	42.31%	45.24%	\$670,176
2/4/2022	ULTA 100 17 JUN 22 380 CALL	179	58	\$30.49	0.489	41.54%	39.05%	\$545,771
1/18/2022	ULTA 100 18 MAR 22 365 CALL	311	41	\$30.50	0.59	42.40%	51.98%	\$945,440
12/22/2021	ULTA 100 18 MAR 22 380 CALL	215	86	\$32.20	0.581	37.26%	50.96%	\$692,300
12/16/2021	ULTA 100 17 JUN 22 440 CALL	608	2	\$24.80	0.387	38.39%	28.84%	\$1,507,840

Top 40 Micro-Cap Profile

ClearPoint Neuro (CLPT) is the smallest name to make the top micro-caps list but is an intriguing small med-tech company with a market cap of \$200M.

CLPT is a medical device company that develops and commercializes innovative platforms for performing minimally invasive surgical procedures in the brain under direct, intra-procedural magnetic resonance imaging, or MRI, guidance. The ClearPoint system is in commercial use in the United States and the European Union with primary applications to target and guide, in an MRI setting, the insertion of deep brain stimulation electrodes and laser catheters into the brain. The SmartFlow cannula has been used in clinical trials to inject certain fluids directly into the brain, thus bypassing the blood-brain barrier and the ClearTrace system is a product candidate still in development, the objective of which is to perform minimally invasive surgical procedures in the heart. The SmartFlow cannula is being used by several pharmaceutical companies to deliver drugs and biologics under such companies' clinical trials.

CLPT estimates that there are more than 55,000 potential neurosurgical procedures per year in the United States in which the ClearPoint system could be used as a navigational platform for functional stereotactic neurosurgery. CLPT systems are being used in more than 60 hospital and the company has commercial relationships with ~ 25 biologics and drug delivery companies. CLPT does have significant customer concentration with its five largest hospitals accounting for 35% of functional neurosurgery navigation disposable product revenues and one Pharma company accounting for ~ 60% of its biologics and drug delivery revenues. CLPT estimates a \$12B TAM across its two divisions.

CLPT trades 8.8X EV/Sales with revenues growing 52.5% in 2019, 14.4% in 2020, and 27% in 2021 and forecasts for 22-25% growth in 2022 and 2023. CLPT is not yet profitable and operates with gross margins in the 68-70% range with significant SG&A and R&D expenses as it tries to scale. CLPT only receives 5% of

revenues from equipment, operating a razor/razorblade model with 95% of revenues from single-use disposables and services. CLPT raised cash last February and has \$55M so it is well-funded for the next four years with usual cash-burn even if it showed zero growth. CLPT indicated on its last earnings call it expects a record number of system placements this year and is in active discussions with 30 to 40 hospitals. CLPT has a vision for its next phase to hit 100 sites doing 100 cases/year providing a \$100M revenue run-rate which will require new products to hit the market and be commercialized.

CLPT is an intriguing long-term own at a \$200M market cap and I came away very impressed with the CEO on its earnings call. The goal of \$100M revenues seems achievable and at a 10X multiple puts this at a \$1B valuation, a five-bagger.

March 11th (W) OpEx Notable Open Interest

Date	Description	Volume	Current	Current Price	Price Change	Current Value	OI Differential
2/4/2022	AAPL 100 (Weeklys) 11 MAR 22 175 PUT	10,424	24,127	\$8.60	-30.30%	\$20,749,220	95.85%
1/31/2022	AAPL 100 (Weeklys) 11 MAR 22 175 PUT	1,053	24,127	\$8.60	-13.76%	\$20,749,220	2148.56%
1/31/2022	AAPL 100 (Weeklys) 11 MAR 22 180 PUT	11,129	11,196	\$13.26	-23.93%	\$14,845,896	0.53%
2/15/2022	BA 100 (Weeklys) 11 MAR 22 215 PUT	1,805	6,589	\$17.55	144.09%	\$11,563,695	252.54%
2/1/2022	AAPL 100 (Weeklys) 11 MAR 22 170 PUT	5,448	24,294	\$4.74	-8.97%	\$11,515,356	236.90%
2/16/2022	AAPL 100 (Weeklys) 11 MAR 22 165 CALL	10,428	16,711	\$4.10	-52.49%	\$6,851,510	51.26%
2/14/2022	AAPL 100 (Weeklys) 11 MAR 22 165 CALL	3,587	16,711	\$4.10	-46.75%	\$6,851,510	325.22%
2/4/2022	AAPL 100 (Weeklys) 11 MAR 22 170 CALL	6,643	33,418	\$1.47	79.30%	\$4,912,446	296.84%
3/3/2022	AAPL 100 (Weeklys) 11 MAR 22 167.5 PUT	12,222	12,222	\$3.60		\$4,399,920	
2/15/2022	BA 100 (Weeklys) 11 MAR 22 210 PUT	1,797	2,094	\$12.95	135.88%	\$2,711,730	7.11%
2/16/2022	AAPL 100 (Weeklys) 11 MAR 22 160 CALL	2,131	3,137	\$7.85	-36.69%	\$2,462,545	20.05%
3/3/2022	SNAP 100 (Weeklys) 11 MAR 22 37.5 PUT	8,281	8,281	\$2.79		\$2,310,399	
2/11/2022	UAL 100 (Weeklys) 11 MAR 22 46 PUT	5,843	5,824	\$3.75	67.41%	\$2,184,000	-1.57%
2/14/2022	DASH 100 (Weeklys) 11 MAR 22 91 CALL	1,038	2,193	\$8.75	-37.05%	\$1,918,875	31.63%
2/4/2022	DASH 100 (Weeklys) 11 MAR 22 91 CALL	628	2,193	\$8.75	-45.31%	\$1,918,875	249.20%
2/7/2022	CZR 100 (Weeklys) 11 MAR 22 80 CALL	2,535	2,347	\$7.47	30.37%	\$1,753,209	-7.71%
2/25/2022	FB 100 (Weeklys) 11 MAR 22 210 CALL	1,510	3,567	\$4.85	-29.20%	\$1,729,995	53.09%
2/11/2022	UAL 100 (Weeklys) 11 MAR 22 45 PUT	5,939	5,877	\$2.93	62.78%	\$1,721,961	-1.34%
3/3/2022	MRNA 100 (Weeklys) 11 MAR 22 135 PUT	4,598	4,598	\$3.65		\$1,678,270	
1/28/2022	JWN 100 (Weeklys) 11 MAR 22 22 CALL	3,006	3,099	\$5.30	181.91%	\$1,642,470	3.09%
2/25/2022	FCX 100 (Weeklys) 11 MAR 22 35 CALL	1,400	1,155	\$13.50	25.35%	\$1,559,250	-18.66%
1/27/2022	DOCU 100 (Weeklys) 11 MAR 22 120 PUT	529	1,070	\$14.15	5.03%	\$1,514,050	102.27%
3/3/2022	LMT 100 (Weeklys) 11 MAR 22 445 PUT	2,329	2,329	\$6.20		\$1,443,980	
2/14/2022	CLF 100 (Weeklys) 11 MAR 22 20.5 CALL	4,033	4,321	\$3.21	453.45%	\$1,387,041	2.86%
3/3/2022	X 100 (Weeklys) 11 MAR 22 29 CALL	6,379	6,379	\$2.08		\$1,326,832	
2/22/2022	AAPL 100 (Weeklys) 11 MAR 22 162.5 PUT	3,545	7,466	\$1.75	45.48%	\$1,306,550	110.61%
3/3/2022	AMD 100 (Weeklys) 11 MAR 22 127 CALL	22,082	22,082	\$0.59		\$1,302,838	
2/22/2022	ABNB 100 (Weeklys) 11 MAR 22 160 PUT	1,534	1,731	\$7.10	21.58%	\$1,229,010	1.17%
2/23/2022	DVN 100 (Weeklys) 11 MAR 22 54 CALL	2,142	2,152	\$5.50	111.54%	\$1,183,600	-5.57%
2/24/2022	MRVL 100 (Weeklys) 11 MAR 22 70 CALL	1,014	3,089	\$3.47	59.17%	\$1,071,883	43.88%
2/17/2022	FB 100 (Weeklys) 11 MAR 22 205 CALL	2,575	1,368	\$7.75	-44.64%	\$1,060,200	-48.14%
2/11/2022	X 100 (Weeklys) 11 MAR 22 26 CALL	3,212	3,474	\$3.05	400.00%	\$1,059,570	-0.09%
3/3/2022	MU 100 (Weeklys) 11 MAR 22 88 CALL	2,283	2,283	\$4.40		\$1,004,520	
3/3/2022	LCID 100 (Weeklys) 11 MAR 22 22 PUT	8,583	8,583	\$1.17		\$1,004,211	

Date	Description	Volume	Current	Current Price	Price Change	Current Value	OI Differential
2/23/2022	DVN 100 (Weeklys) 11 MAR 22 56 CALL	2,017	2,284	\$4.30	-167.08%	\$982,120	5.20%
1/28/2022	JWN 100 (Weeklys) 11 MAR 22 25 CALL	3,006	3,393	\$2.75	-186.46%	\$933,075	12.87%
2/17/2022	PENN 100 (Weeklys) 11 MAR 22 50 CALL	1,173	3,308	\$2.80	2.56%	\$926,240	41.43%
2/10/2022	PENN 100 (Weeklys) 11 MAR 22 50 CALL	1,323	3,308	\$2.80	-23.29%	\$926,240	144.67%
2/25/2022	X 100 (Weeklys) 11 MAR 22 26.5 CALL	3,143	3,183	\$2.85	106.52%	\$907,155	-0.56%
2/17/2022	GRPN 100 (Weeklys) 11 MAR 22 20 PUT	5,128	6,485	\$1.38	-206.67%	\$894,930	25.97%
3/3/2022	MU 100 (Weeklys) 11 MAR 22 93 CALL	4,786	4,786	\$1.83		\$875,838	
2/23/2022	T 100 (Weeklys) 11 MAR 22 22 CALL	4,005	4,033	\$2.08	16.85%	\$838,864	-0.69%
3/3/2022	DKNG 100 (Weeklys) 11 MAR 22 21 PUT	6,097	6,097	\$1.23		\$749,931	
2/25/2022	MRVL 100 (Weeklys) 11 MAR 22 66 CALL	800	1,271	\$5.90	-9.23%	\$749,890	47.96%
2/23/2022	ABNB 100 (Weeklys) 11 MAR 22 150 PUT	2,164	2,554	\$2.84	-39.57%	\$725,336	4.16%
3/3/2022	CZR 100 (Weeklys) 11 MAR 22 80 PUT	3,657	3,657	\$1.88		\$687,516	
2/25/2022	CLF 100 (Weeklys) 11 MAR 22 20 CALL	1,219	1,616	\$3.79	99.47%	\$612,464	-30.94%
3/3/2022	CPRI 100 (Weeklys) 11 MAR 22 64 PUT	3,598	3,598	\$1.64		\$590,072	
2/18/2022	AMD 100 (Weeklys) 11 MAR 22 121 CALL	2,134	1,810	\$2.93	-11.83%	\$530,330	-24.24%
2/16/2022	PYPL 100 (Weeklys) 11 MAR 22 105 CALL	1,502	1,153	\$4.54	-53.20%	\$523,462	-24.74%
3/1/2022	CPNG 100 (Weeklys) 11 MAR 22 26.5 PUT	2,004	2,165	\$2.40	25.65%	\$519,600	7.18%
3/3/2022	MU 100 (Weeklys) 11 MAR 22 95 CALL	3,204	3,204	\$1.58		\$506,232	
2/22/2022	NKE 100 (Weeklys) 11 MAR 22 135 PUT	1,142	1,709	\$2.77	16.06%	\$473,393	19.26%
2/17/2022	EBAY 100 (Weeklys) 11 MAR 22 56 PUT	1,876	2,249	\$1.97	-27.84%	\$443,053	16.23%
2/22/2022	PYPL 100 (Weeklys) 11 MAR 22 110 CALL	1,675	2,118	\$2.09	9.52%	\$442,662	1.19%
3/1/2022	FCX 100 (Weeklys) 11 MAR 22 47 PUT	2,596	3,755	\$1.11	0.89%	\$416,805	40.53%
3/3/2022	HIMX 100 (Weeklys) 11 MAR 22 12 PUT	5,000	5,000	\$0.80		\$400,000	
1/28/2022	FOXA 100 (Weeklys) 11 MAR 22 40 CALL	1,911	1,918	\$2.00	-27.39%	\$383,600	0.37%
3/3/2022	FUTU 100 (Weeklys) 11 MAR 22 40 CALL	2,215	2,215	\$1.71		\$378,765	
2/14/2022	INTC 100 (Weeklys) 11 MAR 22 48 CALL	2,058	2,223	\$1.60	-1.84%	\$355,680	-1.33%
2/22/2022	AMC 100 (Weeklys) 11 MAR 22 17 PUT	3,752	5,478	\$0.63	69.12%	\$345,114	-4.36%
2/24/2022	NCLH 100 (Weeklys) 11 MAR 22 19.5 CALL	3,946	4,628	\$0.66	-1.49%	\$305,448	15.18%
3/1/2022	KSS 100 (Weeklys) 11 MAR 22 55 PUT	3,539	3,373	\$0.89	-54.12%	\$300,197	-13.27%
2/10/2022	KO 100 (Weeklys) 11 MAR 22 63 CALL	3,555	3,872	\$0.65	-4.84%	\$251,680	-26.57%

Disclaimer:

Not Investment Advice or Recommendation

Any descriptions "to buy", "to sell", "long", "short" or any other trade related terminology should not be seen as a recommendation. The Author may or may not take positions in any of the names mentioned, and is not obligated to disclose positions, nor position sizes.

Content is for informational and educational purposes only, and is not to be construed as specific investment advice or recommendations. You alone will need to evaluate the merits and risks associated with the use of this content. Decisions based on information provided are your sole responsibility, and before making any decision on the basis of this information, you should consider (with or without the assistance of a financial and/or securities adviser) whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. Investors should seek qualified professional financial advice regarding the suitability of investing in any securities or following any investment strategies.

No reference to any specific security constitutes a recommendation to buy, sell or hold that security or any other security. Nothing constitutes investment advice or offers any opinion with respect to the suitability of any security, and the views expressed on this website should not be taken as advice to buy, sell or hold any security. In preparing the information contained in this website, OptionsHawk has not taken into account the investment needs, objectives and financial circumstances of any particular investor. This information does not consider the specific investment objectives, financial situation and particular needs of any specific recipient of this information and investments discussed may not be suitable for all investors

Please see full legal disclaimer and terms of the subscription agreement for further details:

Note: Any attempt to copy or forward contents of this email is a violation of your subscriber agreement and can result in termination without refund. Please note your subscriber agreement makes you legally liable for any copyright infringement.